EA201290026A1 - Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) - Google Patents

Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)

Info

Publication number
EA201290026A1
EA201290026A1 EA201290026A EA201290026A EA201290026A1 EA 201290026 A1 EA201290026 A1 EA 201290026A1 EA 201290026 A EA201290026 A EA 201290026A EA 201290026 A EA201290026 A EA 201290026A EA 201290026 A1 EA201290026 A1 EA 201290026A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
risk
treating
analism
reception
Prior art date
Application number
EA201290026A
Other languages
English (en)
Inventor
Брайан Аулт
Клара Хуанг
Эверардус Орлеманс
Джон Р. Плачетка
Марк Состек
Original Assignee
Астразенека Аб
Поузен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43381035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб, Поузен Инк. filed Critical Астразенека Аб
Publication of EA201290026A1 publication Critical patent/EA201290026A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к способу лечения заболевания или расстройства у пациента, имеющего риск развития язвы, связанной с NSAID, путем введения фармацевтической композиции в стандартной лекарственной форме, содержащей напроксен или его фармацевтически приемлемую соль и эзомепразол или его фармацевтически приемлемую соль. Стандартная доза разработана для высвобождения по меньшей мере части эзомепразола независимо от рН (например, при рН 0 или выше), тогда как напроксен не высвобождается до тех пор, пока рН окружающей среды не достигнет 3,5 или выше.
EA201290026A 2009-06-25 2010-06-23 Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) EA201290026A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22042009P 2009-06-25 2009-06-25
US22597009P 2009-07-16 2009-07-16
US31052510P 2010-03-04 2010-03-04
PCT/SE2010/050712 WO2010151216A1 (en) 2009-06-25 2010-06-23 Method for treating a patient at risk for developing an nsaid-associated ulcer

Publications (1)

Publication Number Publication Date
EA201290026A1 true EA201290026A1 (ru) 2012-07-30

Family

ID=43381035

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290026A EA201290026A1 (ru) 2009-06-25 2010-06-23 Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)

Country Status (13)

Country Link
US (3) US8945621B2 (ru)
EP (1) EP2445499A4 (ru)
JP (1) JP2012531409A (ru)
KR (1) KR20120030106A (ru)
CN (1) CN102481293A (ru)
AU (1) AU2010263304A1 (ru)
CA (1) CA2764963C (ru)
EA (1) EA201290026A1 (ru)
IL (1) IL216877A0 (ru)
MA (1) MA33553B1 (ru)
MX (1) MX2011013467A (ru)
SG (1) SG176724A1 (ru)
WO (1) WO2010151216A1 (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2736547C (en) * 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US8420057B2 (en) 2011-09-01 2013-04-16 Qualicaps, Inc. Capsule having broad color spectrum
US8435545B2 (en) 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CA3121746A1 (en) 2017-01-04 2018-07-12 Herriot TABUTEAU Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
EP3999013A4 (en) * 2019-07-15 2023-07-26 R.P. Scherer Technologies, LLC SOFT GEL CAPSULE WITH ENTERIC PROTON PUMP INHIBITOR
KR20230127317A (ko) 2020-12-30 2023-08-31 에이치케이이노엔 주식회사 테고프라잔과 비스테로이드성 항염증 약물을 포함하는약학적 조성물
KR20230125826A (ko) 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
CH647676A5 (fr) 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
US4198390A (en) 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB2105193B (en) 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS59227870A (ja) 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4522826A (en) 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IT1196190B (it) 1984-07-12 1988-11-10 Lisapharma Spa Forma farmaceutica solida orale ad azione sequenziale per la somministrazione di farmaci ad effetto collaterale ulcerogeno
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4766117A (en) 1984-10-11 1988-08-23 Pfizer Inc. Antiinflammatory compositions and methods
US4676984A (en) 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
US4704278A (en) 1984-10-17 1987-11-03 American Home Products Corp (Del) Fluidized magaldrate suspension
DE3603576A1 (de) 1986-02-06 1987-08-13 Code Kaffee Handel Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5043358A (en) 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US4965065A (en) 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US5037815A (en) 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5260333A (en) 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
EP0320550A1 (en) 1987-12-18 1989-06-21 Bristol-Myers Company Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent
GB8805268D0 (en) 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
NZ235877A (en) 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
ES2071312T3 (es) 1990-05-03 1995-06-16 Searle & Co Composicion farmaceutica.
AU7793791A (en) 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition for use in treating pain
WO1991016886A1 (en) 1990-05-03 1991-11-14 G.D. Searle & Co. Pharmaceutical composition containing ibuprofen and a prostaglandin
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
PL166209B1 (pl) 1990-06-20 1995-04-28 Astra Ab Sposób wytwarzania nowych pochodnych benzimidazolu PL
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
JPH06506198A (ja) 1991-03-04 1994-07-14 ワーナー−ランバート・コンパニー 種々な剤形の非ステロイド性抗炎症剤の新規な塩／イオン対
US5409709A (en) 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
ES2130152T3 (es) 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
DE69231281T2 (de) 1991-12-17 2001-03-01 Biovail Technologies Ltd.(N.D.Ges.D.Staates Delaware), Chantilly Zusammensetzung und verfahren zur ulcusprävention und -behandlung
AU3247593A (en) 1991-12-20 1993-07-28 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
US5294433A (en) 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
GR1002332B (el) 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
AU4931693A (en) 1992-09-29 1994-04-26 Mcneil-Ppc, Inc. Ibuprofen-h2 antagonist combinations
CA2110313C (en) 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EP0724441A1 (en) 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5643960A (en) 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
FR2719999B1 (fr) 1994-05-17 1996-08-02 Georges Serge Grimberg Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
EP0723436B1 (en) 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
WO1996005199A1 (de) 1994-08-12 1996-02-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridinsalz
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1996022780A1 (en) 1995-01-27 1996-08-01 The Board Of Regents Of The University Of Texas System Methods of enhancing the therapeutic activity of nsaids and compositions of zwitterionic phospholipids useful therein
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5955451A (en) 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6031549A (en) * 1995-07-19 2000-02-29 Extempo Systems, Inc. System and method for directed improvisation by computer controlled characters
AU6981996A (en) 1995-09-27 1997-04-17 Merck Frosst Canada Inc. Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
US5880731A (en) * 1995-12-14 1999-03-09 Microsoft Corporation Use of avatars with automatic gesturing and bounded interaction in on-line chat session
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
CN1238694A (zh) 1996-11-22 1999-12-15 普罗克特和甘保尔公司 治疗肠胃病用的含铋和nsaid的组合物
EP0941101A1 (en) 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
EA002806B1 (ru) 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
CA2307887A1 (en) 1997-10-31 1999-05-14 Monsanto Company Gellan gum tablet coating
JP4546643B2 (ja) 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
DE19801811B4 (de) 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
EP1056456A4 (en) 1998-01-30 2006-10-25 Sepracor Inc R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
WO1999038512A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
US20020090395A1 (en) 1998-09-10 2002-07-11 Austen John Woolfe Anti-inflammatory pharmaceutical formulations
US8231899B2 (en) 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
JP5026635B2 (ja) 1998-09-10 2012-09-12 ニュコメデ ダンマルク アンパーツセルスカブ 医薬物質の迅速放出医薬組成物
AU757343B2 (en) 1998-09-28 2003-02-20 Capsugel Belgium Nv Enteric and colonic delivery using HPMC capsules
US6485747B1 (en) 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
US6389458B2 (en) * 1998-10-30 2002-05-14 Ideaflood, Inc. Method, apparatus and system for directing access to content on a computer network
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
DE19901687B4 (de) 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
US6183779B1 (en) 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
IL145550A0 (en) 1999-03-26 2002-06-30 Pozen Inc High potency dihydroergotamine compositions
US7546530B1 (en) * 1999-04-15 2009-06-09 Hoshiko Llc Method and apparatus for mapping a site on a wide area network
IL145220A0 (en) 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
CA2277407A1 (en) 1999-07-14 2001-01-14 Bernard Charles Sherman Pharmaceutical tablet comprising an nsaid and misoprostol
US6126816A (en) 1999-07-14 2000-10-03 Ruiz, Jr.; Reuben F. Wastewater treatment device
US6687746B1 (en) * 1999-08-30 2004-02-03 Ideaflood, Inc. System apparatus and method for hosting and assigning domain names on a wide area network
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US8291340B1 (en) * 1999-10-14 2012-10-16 Hoshiko Llc Method and apparatus for providing content to users
US6763379B1 (en) * 1999-10-14 2004-07-13 Ideaflood, Inc. System, apparatus and method for presenting and displaying content on a wide area network
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
SE0000773D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US7370110B2 (en) * 2000-04-18 2008-05-06 Hoshiko Llc Method and system for operating a network server to discourage inappropriate use
US6978252B2 (en) * 2000-04-18 2005-12-20 Ideaflood, Inc. Method and system for transacting with network traffic
US7593864B2 (en) * 2000-04-18 2009-09-22 Brian Mark Shuster Method and apparatus for managing ownership of virtual property
US6862610B2 (en) * 2000-05-08 2005-03-01 Ideaflood, Inc. Method and apparatus for verifying the identity of individuals
US7228327B2 (en) * 2000-05-08 2007-06-05 Hoshiko Llc Method and apparatus for delivering content via information retrieval devices
US7428576B2 (en) * 2000-05-16 2008-09-23 Hoshiko Llc Addressee-defined mail addressing system and method
US7200863B2 (en) * 2000-05-16 2007-04-03 Hoshiko Llc System and method for serving content over a wide area network
US7051362B2 (en) * 2000-05-16 2006-05-23 Ideaflood, Inc. Method and system for operating a network server to discourage inappropriate use
US7899703B2 (en) * 2000-05-16 2011-03-01 Brian Mark Shuster Method and apparatus for providing internet advertising service
US20020019800A1 (en) * 2000-05-16 2002-02-14 Ideaflood, Inc. Method and apparatus for transacting divisible property
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US20020022999A1 (en) * 2000-06-23 2002-02-21 Shuster Brian Mark Method and apparatus for providing audio advertisements in a computer network
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6756879B2 (en) * 2000-07-11 2004-06-29 Ideaflood, Inc. Method and apparatus for securing delivery of goods
US6826546B1 (en) * 2000-08-17 2004-11-30 Ideaflood, Inc. Method and system for licensing a copy of a copyright protected work
US6895236B2 (en) * 2000-08-23 2005-05-17 Ideaflood, Inc. Method for verifying geographical location of wide area network users
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US7029701B2 (en) 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US20020045184A1 (en) 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
EP1363604A2 (en) 2001-02-14 2003-11-26 Glaxo Wellcome S.A. Pharmaceutical formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US7801944B2 (en) * 2001-05-18 2010-09-21 Gary Stephen Shuster Distributed computing using agent embedded in content unrelated to agents processing function
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20100172983A1 (en) * 2001-06-01 2010-07-08 Plachetka John R Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole
WO2002098352A2 (en) * 2001-06-01 2002-12-12 Pozen Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US6930099B2 (en) 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US7465229B2 (en) * 2002-03-26 2008-12-16 Hoshiko Llc Slot-machine game with adjusting payout table
US20040073439A1 (en) * 2002-03-26 2004-04-15 Ideaflood, Inc. Method and apparatus for issuing a non-transferable ticket
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
FR2845917B1 (fr) 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US20040131676A1 (en) 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US7332183B2 (en) 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004062552A2 (en) 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2004064815A1 (en) 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
US8290948B2 (en) * 2003-06-30 2012-10-16 Hoshiko, Llc Method and apparatus for content filtering
US7835294B2 (en) * 2003-09-03 2010-11-16 Gary Stephen Shuster Message filtering method
JP2005145894A (ja) 2003-11-17 2005-06-09 Takeda Chem Ind Ltd 固形製剤
US20050163847A1 (en) 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
WO2005074930A1 (en) 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids
WO2005074536A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US7460737B2 (en) * 2004-02-12 2008-12-02 Hoshiko Llc Method and apparatus for photograph finding
US20050227949A1 (en) 2004-04-07 2005-10-13 Nasrola Edalatpour Compositions and methods for treatment of viral and bacterial infections
US7813917B2 (en) * 2004-06-22 2010-10-12 Gary Stephen Shuster Candidate matching using algorithmic analysis of candidate-authored narrative information
EP1811975A2 (en) 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
US20060165797A1 (en) 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US20060178348A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
US20080092065A1 (en) * 2005-02-04 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Third party control over virtual world characters
US8566111B2 (en) * 2005-02-04 2013-10-22 The Invention Science Fund I, Llc Disposition of component virtual property rights
US20070013691A1 (en) * 2005-07-18 2007-01-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Supervisory authority in virtual world environment
US20060177504A1 (en) 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
EP1726301A1 (en) 2005-05-24 2006-11-29 Flamel Technologies Oral pharmaceutical composition for treating a COX-2 mediated condition
EP1726300A1 (en) 2005-05-24 2006-11-29 Flamel Technologies Oral pharmaceutical formulation for the prevention and/or the treatment of cardiovascular and inflammatory diseases
US7980934B2 (en) * 2005-09-08 2011-07-19 Hoshiko, Llc Gaming method
JP2009508398A (ja) * 2005-09-09 2009-02-26 ホシコ・リミテッド・ライアビリティ・カンパニー ネットワークルータ・セキュリティ方法
WO2007035611A2 (en) * 2005-09-16 2007-03-29 Hoshiko, Llc Low power mode for portable computer system
US7874521B2 (en) * 2005-10-17 2011-01-25 Hoshiko Llc Method and system for aviation navigation
US10148905B2 (en) * 2005-10-19 2018-12-04 Intellectual Ventures I Llc Digital medium with hidden content
US20070093232A1 (en) * 2005-10-21 2007-04-26 Shuster Gary S Management of an alert signal for a telecommunications device
US8577698B2 (en) * 2005-10-25 2013-11-05 Intellectual Ventures I Llc Retail price hedging
US7937320B2 (en) * 2005-11-14 2011-05-03 Hoshiko, Llc Managed purchasing account for defined commodities
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
EP1965774A2 (en) 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2644435C (en) 2006-03-06 2015-04-07 Pozen Inc. Dosage forms for administering combinations of drugs
US7744464B2 (en) * 2006-09-19 2010-06-29 Gary Stephen Shuster Method of managing a card game, a computer implementation thereof, and a card game kit
US8683386B2 (en) * 2006-10-03 2014-03-25 Brian Mark Shuster Virtual environment for computer game
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US7803042B2 (en) * 2007-01-17 2010-09-28 Gary Stephen Shuster Card game with common card removal
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
WO2008109798A2 (en) * 2007-03-07 2008-09-12 Ideaflood, Inc. Multi-instance, multi-user animation platforms
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
US7914144B2 (en) * 2007-05-02 2011-03-29 Gary Stephen Shuster Eyewear with pinhole aperture and lens
US7804744B2 (en) * 2007-05-03 2010-09-28 Gary Stephen Shuster Optically-readable disk with copy protection device
US7916619B2 (en) * 2007-05-03 2011-03-29 Gary Stephen Shuster Optically-readable disk with copy protection device
US8126971B2 (en) * 2007-05-07 2012-02-28 Gary Stephen Shuster E-mail authentication
US20090023771A1 (en) 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
US7769806B2 (en) * 2007-10-24 2010-08-03 Social Communications Company Automated real-time data stream switching in a shared virtual area communication environment
US7809789B2 (en) * 2007-10-25 2010-10-05 Brian Mark Shuster Multi-user animation coupled to bulletin board
US8049756B2 (en) * 2007-10-30 2011-11-01 Brian Mark Shuster Time-dependent client inactivity indicia in a multi-user animation environment
CA2740974A1 (en) 2008-05-30 2009-12-03 Pozen Inc. Dosage forms for the rapid and sustained elevation of gastric ph
US8471843B2 (en) * 2008-07-07 2013-06-25 International Business Machines Corporation Geometric and texture modifications of objects in a virtual universe based on real world user characteristics
US20100005028A1 (en) * 2008-07-07 2010-01-07 International Business Machines Corporation Method and apparatus for interconnecting a plurality of virtual world environments
US9268385B2 (en) * 2008-08-20 2016-02-23 International Business Machines Corporation Introducing selective energy efficiency in a virtual environment
CA2736547C (en) * 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US8108774B2 (en) * 2008-09-26 2012-01-31 International Business Machines Corporation Avatar appearance transformation in a virtual universe
EA021112B1 (ru) 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
US9610502B2 (en) * 2009-07-10 2017-04-04 International Business Machines Corporation Use of real time location information for user authentication and authorization in virtual environments
US8893000B2 (en) * 2009-08-26 2014-11-18 International Business Machines Corporation Relocation between virtual environments based upon promotional and alert conditions
US9785909B2 (en) * 2009-08-27 2017-10-10 International Business Machines Corporation Preventing propagation of malicious content in a virtual universe
US9256896B2 (en) * 2009-08-27 2016-02-09 International Business Machines Corporation Virtual universe rendering based on prioritized metadata terms
US20110047828A1 (en) * 2009-09-02 2011-03-03 Gary Stephen Shuster Remotely controlled footwear disruptor
US20120030289A1 (en) * 2010-07-30 2012-02-02 Avaya Inc. System and method for multi-model, context-sensitive, real-time collaboration
US8717447B2 (en) * 2010-08-20 2014-05-06 Gary Stephen Shuster Remote telepresence gaze direction
US8949964B2 (en) * 2010-08-25 2015-02-03 Gary Stephen Shuster Security key entry using ancillary input device
US20120059886A1 (en) * 2010-08-30 2012-03-08 Gary Stephen Shuster Reply message handling for transient group
US20140372912A9 (en) * 2010-10-30 2014-12-18 Aaron D. Cohen Multi-Dimensional Enhanced World View Experiences, Related Systems and Software, Methods of Use and Production Thereof
EP2745462B1 (en) * 2011-08-18 2021-10-20 Pfaqutruma Research LLC Systems and methods of virtual world interaction

Also Published As

Publication number Publication date
CA2764963C (en) 2016-11-01
CA2764963A1 (en) 2010-12-29
US8945621B2 (en) 2015-02-03
SG176724A1 (en) 2012-01-30
US20150202193A1 (en) 2015-07-23
EP2445499A4 (en) 2013-02-27
MX2011013467A (es) 2012-02-13
US20100330179A1 (en) 2010-12-30
IL216877A0 (en) 2012-02-29
US20160166558A1 (en) 2016-06-16
CN102481293A (zh) 2012-05-30
AU2010263304A1 (en) 2012-02-02
WO2010151216A1 (en) 2010-12-29
MA33553B1 (fr) 2012-09-01
JP2012531409A (ja) 2012-12-10
KR20120030106A (ko) 2012-03-27
EP2445499A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
DK1765349T3 (da) Opioider til behandling af kronisk obstruktiv lungesygdom
NZ714963A (en) Compositions and methods for treating anemia
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
EA201000855A1 (ru) Способ и средства для достижения бронхиальной релаксации
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
PH12015500823A1 (en) Modified release formulations for oprozomib
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
TN2011000662A1 (en) Method for treating a patient at risk for developing an nsaid-associated ulcer